EpCAM适配体修饰的碳@二氧化锰纳米花用于协同药物-纳米酶治疗变应性鼻炎
EpCAM aptamer modified carbon@manganese dioxide nanoflower for synergistic drug-nanozyme allergic rhinitis treatment.
文献信息
| PMID | 42718604 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Leichao Zhang |
| 作者单位 | Department of Pathology, China-Japan Union Hospital of Jilin University, 126 Xian Tai Street, Changchun, Jilin, 130000, PR China. |
| 期刊 | Materials today. Bio |
| SCI 分区 | Q1 |
| IF | 11.4 |
| 研究类型 | 基础研究 · 基础／转化 |
| 所属专科 | 鼻科 |
中文摘要
变应性鼻炎（AR）是一种常见的上呼吸道过敏性疾病，显著影响患者的生活质量。在本研究中，我们开发了一种用于治疗变应性鼻炎（AR）的多功能纳米酶-药物协同治疗纳米系统。该纳米系统称为EpCAM适配体修饰的碳@二氧化锰纳米花（Apt-C@MnO2 NFs），结合多孔碳纳米球和MnO2纳米酶，以实现协同清除活性氧（ROS）。EpCAM适配体（Apt）是一种上皮细胞黏附分子。所设计的材料经EpCAM适配体修饰，赋予其对上皮细胞突出的靶向能力。PEG修饰促进NFs更快穿透黏液，而Apt使NFs能够特异性靶向人鼻上皮细胞（HNEPc）。此外，它能够有效负载并持续释放抗炎药物布地奈德（BUD）。体外实验证明该系统能够靶向HNEPc、递送药物、表现出多酶活性并调节炎症因子。小鼠体内研究显示，Apt-C@MnO2 NFs能够恢复线粒体生物发生相关蛋白的表达，减少炎症细胞浸润，调节炎症通路，并缓解AR症状。该研究为AR治疗提供了新方法，提供了一种具有显著抗炎作用和成像追踪能力的多功能系统。这一创新治疗策略将纳米酶技术与靶向药物递送相结合，以实现AR的有效治疗。
英文摘要
Allergic rhinitis (AR) is a prevalent upper respiratory allergic disorder that significantly impacts patients' quality of life.In this research, we developed a multifunctional nanozyme-drug synergistic therapy nanosystem for the treatment of allergic rhinitis (AR). The nanosystem, called EpCAM aptamer modified carbon@manganese dioxide nanoflower (Apt-C@MnO2 NFs), combines porous carbon nanospheres and MnO2 nanozymes to achieve synergistic reactive oxygen species (ROS) scavenging. EpCAM aptamer (Apt) is an epithelial cell adhesion molecule. The designed material was modified with EpCAM aptamers, endowing it with prominent targeting capability to epithelial cells. The modification with PEG facilitates the penetration of NFs through mucus more rapidly, and the Apt enables the NFs to specifically target human nasal epithelial cells (HNEPc). In addition, it can effectively load and sustainably release the anti-inflammatory drug budesonide (BUD). In vitro experiment demonstrated the system's ability to target HNEPc, deliver drugs, exhibit multi-enzyme activity, and regulate inflammatory factors. In vivo studies in mice showed that Apt-C@MnO2 NFs could restore the expression of mitochondrial biogenesis-related proteins, reduce inflammatory cell infiltration, regulate inflammatory pathways, and alleviate AR symptoms. The research provides a new approach for AR therapy, offering a multifunctional system with significant anti-inflammatory effects and imaging tracking capabilities. This innovative therapeutic strategy combines nanozyme technology with targeted drug delivery to achieve effective treatment of AR.